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Heteroplasmic mitochondrial DNA (mtDNA) mutations (mutations present only in a subset of cellular mtDNA
copies) arise de novo during the normal ageing process or may be maternally inherited in pedigrees with
mitochondrial disease syndromes. A pathogenic mtDNA mutation causes respiratory chain deﬁciency only
if the fraction of mutated mtDNA exceeds a certain threshold level. These mutations often undergo apparently
random mitotic segregation and the levels of normal and mutated mtDNA can vary considerably between
cells of the same tissue. In human ageing, segregation of somatic mtDNA mutations leads to mosaic respir-
atory chain deﬁciency in a variety of tissues, such as brain, heart and skeletal muscle. A similar pattern of
mutation segregation with mosaic respiratory chain deﬁciency is seen in patients with mitochondrial disease
syndromes caused by inherited pathogenic mtDNA mutations. We have experimentally addressed the role of
mosaic respiratory chain deﬁciency in ageing and mitochondrial disease by creating mouse chimeras with a
mixture of normal and respiratory chain-deﬁcient neurons in cerebral cortex. We report here that a low pro-
portion (>20%) of respiratory chain-deﬁcient neurons in the forebrain are sufﬁcient to cause symptoms,
whereas premature death of the animal occurs only if the proportion is high (>60–80%). The presence of
neurons with normal respiratory chain function does not only prevent mortality but also delays the age at
which onset of disease symptoms occur. Unexpectedly, respiratory chain-deﬁcient neurons have adverse
effect on normal adjacent neurons and induce trans-neuronal degeneration. In summary, our study deﬁnes
the minimal threshold level of respiratory chain-deﬁcient neurons needed to cause symptoms and also
demonstrate that neurons with normal respiratory chain function ameliorate disease progression. Finally,
we show that respiratory chain-deﬁcient neurons induce death of normal neurons by a trans-neuronal
degeneration mechanism. These ﬁndings provide novel insights into the pathogenesis of mosaic respiratory
chain deﬁciency in ageing and mitochondrial disease.
INTRODUCTION
Mutations of mitochondrial DNA (mtDNA) are common
causes of human genetic disease (1,2) and are also heavily
implicated in the ageing process (3,4). Heteroplasmic
mutations of mtDNA typically undergo an apparently
random segregation in somatic tissues and they will impair
respiratory chain function if they are present above a certain
threshold level (5). This uneven distribution of mutated
mtDNA among cells in a tissue often creates a mosaic
pattern of respiratory chain deﬁciency in patients with mito-
chondrial diseases caused by inherited pathogenic mtDNA
mutations.
It has been recognized for almost two decades that acquired
mtDNA mutations (6–11) and decreased respiratory chain
capacity (12–14) are associated with mammalian ageing.
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proof-reading-deﬁcient mtDNA polymerase have shown that
high levels of somatic mtDNA mutations in the mouse
impair respiratory chain function and cause a variety of pre-
mature ageing phenotypes, such as osteoporosis, hair loss, alo-
pecia, lean-ness, weight loss, reduced fertility and heart
enlargement (15). Somatic mtDNA mutations thus have the
capacity to cause premature ageing phenotypes, but it has
been questioned whether the levels observed in normal
ageing are sufﬁcient to impair respiratory chain function
(16). When discussing this issue, it is important to recognize
that somatic mtDNA mutations are subject to the same appar-
ently random mitotic segregation as inherited mtDNA
mutations (5). Ageing humans invariably develop focal respir-
atory chain deﬁciency (14,17–19) in a variety of tissues, such
as heart (20), skeletal muscle (21), colon (19) and brain (18,
22,23). There is good evidence to support the hypothesis
that clonal expansion of somatic mtDNA mutations is the
main factor explaining this phenomenon (14,17–19).
The pathogenesis of focal respiratory chain deﬁciency is
poorly understood and the fraction of respiratory chain-
deﬁcient cells that need to be present in an organ in order to
cause symptoms has not been previously deﬁned. In this
study, we generated chimeras between normal mice and mito-
chondrial late-onset neurodegeneration (MILON) mice (24) to
create mice with varying proportions of focal respiratory chain
deﬁciency in forebrain neurons. The MILON mice have a con-
ditional knockout for mitochondrial transcription factor A
(Tfam) in neocortex and medial parts of hippocampus,
which leads to adult onset of progressive respiratory chain
deﬁciency in large forebrain neurons, neurodegeneration and
premature death (24). Characterization of a large number of
mouse chimeras show that a rather low proportion (.20%)
of respiratory chain-deﬁcient neurons in the forebrain is sufﬁ-
cient to cause clinical symptoms, whereas premature death of
the animal occurs only if the proportion is high (.60–80%).
The presence of normal neurons leads to later onset of disease
and reduced mortality. Unexpectedly, respiratory chain-
deﬁcient neurons induce degeneration of normal adjacent
neurons by a trans-neuronal mechanism. These ﬁndings shed
new light on the pathogenesis of focal respiratory chain
deﬁciency in mitochondrial disease and ageing.
RESULTS
We used an embryo aggregation procedure to generate mouse
chimeras between LacZ embryos and MILON embryos
(Fig. 1A). The LacZ embryos are heterozygous offspring
from the ROSA26 mice and express LacZ ubiquitously
(25,26). The MILON mice are conditional knockouts with
postnatal inactivation of the gene encoding mitochondrial tran-
scription factor A (Tfam) in neurons of neocortex and medial
parts of the hippocampus (24). Conditional knockout of
TFAM causes mtDNA depletion, severely reduced mtDNA
expression and a profound respiratory chain deﬁciency
(24,27,28), because the TFAM protein is critical for mainten-
ance (29,30) and transcription of mtDNA (31). We isolated a
total of 10
3 LacZ embryos and aggregated them with 10
3
embryos that were either control embryos or MILON embryos
(Fig. 1A). We obtained 781 fused embryos and 501 of these
developed to at least the eight-cell stage in vitro and were
subsequently implanted into pseudopregnant foster mothers.
A total of 216 pups were born and genotyped by polymerase
chain reaction (PCR) analysis of tail DNA. We excluded 84
animals because of non-chimeric genotype (n ¼ 71) or
because of inconsistent results from repeated genotyping
(n ¼ 13). We thus obtained a total of 132 chimeric mice,
which were either MILON chimeras (n ¼ 66) or control chi-
meras (n ¼ 66), and these chimeras were used for the sub-
sequent studies.
We used a Southern blot assay to quantify chimera compo-
sition based on the fact that cells derived from control (geno-
type Tfam
loxP/Tfam
loxP) or MILON embryos (genotype
Tfam
loxP/Tfam
loxP, þ/CamKII-cre) are homozygous for the
Tfam
loxP allele, whereas cells derived from LacZ embryos
are homozygous for the wild-type (Tfam
þ) allele (Fig. 1B
and C). The relative amount of Tfam
loxP alleles thus reﬂects
the contribution of control or MILON cells to the chimeras
(Fig. 1B). The composition of the chimeras was assessed by
Southern blot analyses of cerebellum as this region of the
brain is unaffected by the neuron-speciﬁc Tfam knockout
and the subsequent nerve cell loss occurring in MILON
mice (24). Chimeras had an even distribution of various
levels of control (Fig. 2A) or MILON cells (Fig. 2B) in cer-
ebellum. Next, we investigated whether the grade of chimer-
ism in cerebellum, as determined by Southern blot analyses,
was representative of the grade of chimerism, as determined
by histochemical staining for LacZ enzyme activity, in
neurons of neocortex and the dentate gyrus (Fig. 2C and D).
The control or MILON cell contribution in neocortex and
the dentate gyrus was deﬁned as the proportion of neurons
that did not express LacZ. In control chimeras there was a
linear correlation between the grade of chimerism in cerebel-
lum and neocortex (Fig. 2C) or the dentate gyrus (Fig. 2D).
We thus conclude that the observed chimerism in cerebellum
is a good indicator of the grade of chimerism in neocortex and
the dentate gyrus of controls.
We also performed histochemical stainings to determine the
distribution of LacZ-expressing cells in the dentate gyrus
(Fig. 3) and neocortex (not shown) of MILON and control chi-
meras with widely varying levels of chimerism according to
Southern blot analysis of DNA from cerebellum. We found
that the LacZ-expressing cells were evenly distributed
throughout the dentate gyrus (Fig. 3). The aggregation proto-
col we used for generating chimeras thus leads to a ﬁnely dis-
persed mixture of the two cell types, consistent with the
observations in other types of mouse chimeras (32).
We have previously demonstrated that MILON mice
develop a massive nerve cell loss in different regions of neo-
cortex and medial hippocampus at the end of their life (24). As
expected, MILON cells were encountered at less than the
expected frequency in neocortex of MILON chimeras
(Fig. 2C), indicating a substantial loss of respiratory chain-
deﬁcient neurons in this region. There was no clear loss of
neurons in the dentate gyrus as demonstrated by the very
good correlation between levels of chimerism in cerebellum
and the dentate gyrus in MILON chimeras (Fig. 2D). The
reason for the preservation of nerve cells in the dentate
gyrus of MILON chimeras can be that this region is affected
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death therefore may occur before extensive cell death
becomes apparent in this region. It is also possible that
compensatory neurogenesis in the dentate gyrus may mask
an ongoing cell loss, consistent with our previous observation
of PCNA-positive nerve cell clusters indicative of neurogen-
esis in the dentate gyrus of end-stage MILON mice (24).
We used a clinical assessment scale to determine age at
onset of symptoms and followed the lifespan (Fig. 4A–C) in
cohorts of pure MILON mice (n ¼ 25), control chimeras
(n ¼ 57) and MILON chimeras (n ¼ 64). The genetically
determined neurodegeneration in MILON mice invariably
caused symptoms and premature death (Fig. 4A), consistent
with our previous results from studies of these mice (24).
Only three of the control chimeras developed symptoms and
no animals in this cohort died during the 8-month-long
follow-up period (Fig. 4B). These results demonstrate that chi-
merism per se does not cause clinical symptoms or substan-
tially reduced lifespan.
The subset of MILON chimeras that developed clinical
symptoms had a signiﬁcantly (P , 5.0   10
25) higher mean
age at onset of symptoms (mean+1SD ¼ 5.6+0.6 months,
range, r ¼ 4.8–7.0 months) (Fig. 4C) than MILON mice
(5.1+0.2 months, r ¼ 4.8–5.5 months) (Fig. 4A). In
addition, only about half of the symptomatic chimeras died
(Fig. 4C). We also studied the correlation between MILON
cell contribution in cerebellum and occurrence of symptoms
or death in chimeras. Symptoms started to appear in chimeras
with low contribution of MILON cells (.20%) and became
much more prevalent as the MILON contribution increased
(Fig. 4D). Death only occurred in chimeras with a high
(.60%) contribution of MILON cells (Fig. 4E). All of the chi-
meras with a MILON cell contribution .80% developed
symptoms and most of these animals died. The MILON chi-
meras that died had a lifespan (5.6+0.3 months, r ¼ 5.2–
6.4 months), which was not signiﬁcantly different (P ¼ 0.32)
from that of MILON mice (5.6+0.2 months; r ¼ 5.2–6.0
months).
We performed FluoroJade staining (33,34) of control and
MILON chimera brain sections and found evidence for neuro-
degeneration only in MILON chimeras. Chimeras with a high
contribution of MILON cells showed massive neurodegenera-
tion in medial hippocampus and neocortex (Fig. 5A and B).
The pattern of neurodegeneration observed in MILON
Figure 1. Creation of mouse chimeras. (A) Control mice were crossed with mitochondrial late-onset neurodegeneration (MILON) mice to generate control
embryos (genotype Tfam
loxP /Tfam
loxP, indicated by green color) and MILON embryos (genotype Tfam
loxP/Tfam
loxP, þ/CaMKII-cre, indicated by red color).
Homozygous ROSA26 mice (LacZ/LacZ) were crossed with C57BL/6J mice to generate LacZ embryos (genotype þ/LacZ, indicated by blue color). Embryo
aggregations were performed by mixing control embryos and LacZ embryos or MILON embryos and LacZ embryos to generate control chimeras and
MILON chimeras. (B) Genotyping of mouse chimeras using Southern blot analysis. DNA was digested with the restriction endonuclease BamHI and Southern
blots were hybridized with a radioactively labeled probe covering the genomic regions surrounding exon 5 of the Tfam gene. The wild-type allele (Tfam
þ) cor-
responds to a fragment of 7.5 kb, the non-recombined loxP-ﬂanked allele (Tfam
loxP) corresponds to a fragment of 4.7 kb and the knock-out allele (Tfam
2) cor-
responds to a fragment of 9.5 kb (upper panel). Genotyping of cerebellar DNA from chimeras was performed to assess levels of chimerism (lower panel). The
wild-type Tfam allele (Tfam
þ) corresponds to cells derived from the LacZ embryo. The loxP-ﬂanked Tfam allele (Tfam
loxP) corresponds to cells derived from
either control embryos or MILON embryos. Additional genotyping to determine the presence of the CaMKII-cre transgene was performed to distinguish between
chimeras containing control or MILON cells. The knockout Tfam allele (Tfam
2) is not present in cerebellum as cells derived from MILON embryos only express
cre-recombinase in neocortex and hippocampus. The ratio between Tfam
þ and Tfam
loxP alleles in cerebellum of individual chimeras thus corresponds to the level
of chimerism, expressed as the percentage of Tfam
loxP alleles.
1420 Human Molecular Genetics, 2008, Vol. 17, No. 10chimeras of this study (Fig. 5A and B) is very similar to the
previously described pattern in MILON mice (24). As shown
above, the presence of neurons with normal respiratory
chain function delayed the onset of symptoms and prevented
death in MILON chimeras (Fig. 4C). However, we also inves-
tigated whether respiratory chain-deﬁcient neurons may exert
a negative inﬂuence on neurons with normal respiratory chain
function (LacZ-expressing neurons) in neocortex of MILON
chimeras. We detected few LacZ-expressing and FluoroJade-
positive neurons in control chimeras, whereas we found an
increased number of such neurons in the neocortex of
MILON chimeras (Fig. 5C and D). Respiratory chain-deﬁcient
neurons thus induce degeneration of neurons with a normal
respiratory chain function. These trans-neuronal degeneration
events increased if the contribution of MILON cells was
high in the chimeras (Fig. 5E). In chimeras with .80%
contribution of MILON cells 1% of total nerve cell
degeneration in cortex was trans-neuronal (Fig. 5F). There is
a low amount (,20%) of cortical neurons with normal respir-
atory chain function in chimeras with high contribution
(.80%) of MILON cells and therefore a substantial
proportion (1:20) of these neurons degenerate by this
trans-neuronal mechanism.
DISCUSSION
Pathogenic mutations of mtDNA are often heteroplasmic and
undergo mitotic segregation to create a mosaic pattern of res-
piratory chain deﬁciency in various organs. The role of this
mosaicism in the pathogenesis of mitochondrial dysfunction
in disease and ageing has been difﬁcult to assess experimen-
tally. We have now addressed this issue by analyzing mouse
chimeras with mosaic respiratory chain deﬁciency in cerebral
forebrain. We have previously demonstrated that respiratory
chain-deﬁcient neurons are prone to undergo apoptosis (24,35)
Figure 2. Level of chimerism in cerebellum, neocortex and dentate gyrus of chimeras as assessed by Southern blot analysis (proportion of Tfam
loxP alleles) or by
enzyme histochemistry (proportion of LacZ-expressing cells). (A, B) Level of chimerism of control chimeras (blue bars; n ¼ 63) and mitochondrial late-onset
neurodegeneration (MILON) chimeras (black bars; n ¼ 58) assessed by Southern blot analysis of DNA from cerebellum. Each bar represents one animal. Bars
indicate mean levels+1 SD. (C) Correlation between levels of chimerism in neocortex (proportion of neurons not expressing LacZ) and cerebellum (proportion
of Tfam
loxP alleles) of different control chimeras (n ¼ 32; blue dots) and MILON chimeras (n ¼ 32; red dots). Neurons with nuclear staining for Hoechst 33342
but lacking LacZ enzyme activity were classiﬁed as non-LacZ-expressing neurons. There is a linear correlation (blue line; r
2 ¼ 0.81; P ¼ 2.5   10
212) between
levels of chimerism in neocortex and cerebellum of control chimeras. The level of chimerism in neocortex in comparison with cerebellum is generally lower in
MILON chimeras (best ﬁtted red line shown) indicating cell loss. (D) The correlation between levels of chimerism in the dentate gyrus (proportion of neurons not
expressing LacZ) and cerebellum (proportion of Tfam
loxP alleles) of different control chimeras (n ¼ 50; blue dots) and MILON chimeras (n ¼ 35; red dots). The
levels of chimerism in neocortex and cerebellum show a linear correlation in control chimeras (blue line; r
2 ¼ 0.80; P ¼ 1.7   10
218) and MILON chimeras (red
line; r
2 ¼ 0.81; P ¼ 1.8   10
213).
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the forebrain of high-grade MILON chimeras. Relatively low
levels (.20%) of respiratory chain-deﬁcient large forebrain
neurons are sufﬁcient to cause clinical symptoms, whereas
animal death only occurs if a large proportion of the neurons
(.60%) are affected. All animals with very high levels
(.80%) of respiratory chain-deﬁcient neurons in neocortex
and hippocampus develop symptoms and most of them die
from neurodegeneration.
The proportion of respiratory chain-deﬁcient neurons in the
ageing human hippocampus (1%) is well below the
threshold level (20%) needed to cause clinical symptoms
in chimeric mice (22). However, it should be emphasized
that studies of ageing human brains only provide a ‘snap-shot’
Figure 3. Analysis of chimerism in the dentate gyrus. LacZ staining of the dentate gyrus was performed in series (n ¼ 60) of different control and mitochondrial
late-onset neurodegeneration chimeras. The sections are ordered according to increasing mean levels of chimerism (proportion of Tfam
lox alleles) in cerebellum
as follows (starting at the top from left to right): row 1, 0–6%; row 2, 7–19%; row 3, 21–27%; row 4, 32–39%; row 5, 40–49%; row 6, 51–58%; row 7, 62–
68%; row 8, 71–79%; row 9, 82–89%; row 10, 91–100%.
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mice have a genetically deﬁned narrow temporal onset of neu-
rodegeneration (24). It is quite possible that the continuously
ongoing formation of respiratory chain-deﬁcient neurons in
the ageing human brain may lead to a substantial cell loss
over time (22). In addition, there is focal respiratory chain
deﬁciency in a variety of organs in aged humans and the
combined cell loss in all tissues may be substantial and
impact lifespan.
We observed a signiﬁcant loss of healthy neurons because
of a trans-neuronal degeneration mechanism in the chimeric
mice. It has been suggested that neurons are connected in
trophic units (36), which may explain the observed trans-
neuronal degeneration. The ageing process is likely multi-
factorial and determined by accumulated damage to a
variety of cellular maintenance systems (37). Therefore,
such trans-neuronal degeneration may be even more pro-
nounced in the normal ageing process when the respiratory
chain-deﬁcient neurons are surrounded by neurons with
other types of acquired age-associated defects (37). In mito-
chondrial disease, the nerve cell loss may be additionally
enhanced by the presence of respiratory chain deﬁciency in
non-neuronal cells such as astrocytes and other types of glial
cells. Our experimental results may also be of relevance for
a variety of degenerative processes causing cell death in the
nervous system (38), e.g. ischemic stroke and Alzheimer
disease, because trans-neuronal degeneration may enhance
the consequence of various types of primary lesions causing
nerve cell death.
In summary, we have experimentally deﬁned the minimal
threshold level of respiratory chain-deﬁcient neurons in cer-
ebral cortex that are needed to cause clinical symptoms or
death. We demonstrate that the presence of normal neurons
delay onset of disease and prevent death. Finally, we identify
trans-neuronal degeneration as a novel mechanism creating
additional nerve cell loss. These ﬁndings shed new light on
the pathogenesis of mosaic respiratory chain deﬁciency in
ageing and mitochondrial disease.
Figure 4. Observation of clinical symptoms and determination of lifespan in chimeras. Age at onset of symptoms was scored by a clinical assessment scale and is
indicated by gray lines. Age at death (or age at onset grave symptoms requiring euthanasia) was determined and is indicated by black lines. (A) Symptoms and
survival in pure mitochondrial late-onset neurodegeneration (MILON) mice (n ¼ 25). (B) Symptoms and survival in control chimeras (n ¼ 57). (C) Symptoms
and survival in MILON chimeras (n ¼ 63). (D) Relationship between grade of chimerism and occurrence of symptoms in MILON chimeras. (E) Relationship
between grade of chimerism and occurrence of death in MILON chimeras.
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Creation of chimeras
Matings to obtain embryos for aggregation were performed
after superovulation of female mice at age 8–12 weeks. The
mice were ﬁrst injected i.p. with 7.5 IU pregnant mare
serum (Intervet, The Netherlands) and 48 h later injected i.p.
with 7.5 IU chorionic gonadotrophin hormone (HCG; Inter-
vet). Males were added to the cages after the second injection.
Female or male mice of the genotype Tfam
loxP/Tfam
loxP were
mated to mice of the opposite sex with the genotype Tfam
loxP/
Tfam
loxP, þ/CaMKII-cre. This cross is expected to give 50%
Tfam
loxP/Tfam
loxP embryos and 50% Tfam
loxP/Tfam
loxP,
þ/CaMKII-cre embryos. We used the same protocol to super-
ovulate and mate ROSA26 mice, which are homozygous for
LacZ gene (LacZ/LacZ), and C57BL/6 mice to obtain
embryos heterozygous for LacZ (þ/LacZ). Pregnant females
were killed 55 h after the HCG injection and the uterus was
removed. The oviducts and uterus were dissected and ﬂushed
with M2 (Sigma) medium and embryos at the eight-cell stage
up to the early blastocyst stage were recovered and incubated in
KSOM (Molecular Biotechnologies) media. We obtained
a total of 1094 embryos of the genotype Tfam
loxP/Tfam
loxP or
Tfam
loxP/Tfam
loxP, þ/CaMKII-creand1003embryosofthegen-
otype þ/LacZ. The zona pellucida was removed from the
embryos by exposing them to acidic Tyrodes for 30–120 s
Figure 5. Neurodegeneration and trans-neuronal degeneration in mitochondrial late-onset neurodegeneration (MILON) chimeras. (A) Fluorescence microscopy
to detect FluoroJade staining in a brain section of a MILON chimera with 90% Tfam
loxP alleles in cerebellum. Massive neurodegeneration is evident in the medial
hippocampus (upper right arrow), the somatosensory cortex (upper left arrow) and the piriform cortex (lower left arrow). (B) Higher magniﬁcation of area con-
taining the neocortex region indicated by the upper left arrow in (A). (C) Combined image obtained by ﬂuorescence microscopy to detect FluoroJade staining
(green) and bright ﬁeld microscopy for immunohistochemical detection of LacZ expression (red) in the neocortex of a MILON chimera with 56% Tfam
loxP
alleles in cerebellum. Arrows indicate LacZ-expressing neurons undergoing trans-neuronal degeneration. (D) Deconvolution microscopy image demonstrating
the presence of FluoroJade (green) and LacZ (red) in a single neuron undergoing trans-neuronal degeneration in the neocortex of a MILON chimera with 65%
Tfam
loxP alleles in cerebellum. The xz and yz projections (0.3 mm thick, 32 stacks) are shown. (E) The correlation between levels of chimerism (proportion of
Tfam
loxP alleles in cerebellum) and trans-neuronal degeneration (FluoroJade-positive neurons expressing LacZ) in control chimeras (gray bars) and MILON
chimeras (black bars). (F) The proportion of degenerating neurons (FluoroJade-positive neurons) that show evidence of trans-neuronal degeneration (FluoroJade-
positive neurons expressing LacZ) at different levels of chimerism (proportion of Tfam
loxP alleles in cerebellum).
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the genotype Tfam
loxP/Tfam
loxP or Tfam
loxP/Tfam
loxP, þ/
CaMKII-cre were aggregated with þ/LacZ embryos in
microwells with KSOM (Molecular Biotechnologies) medium
covered with OVOIL (Vitolife). Aggregations were performed
at 378C for 28 h in an incubator with 5% CO2 and saturated
humidity. Fused embryos that had developed to the blastocyst
stage were implanted into 2.5-day pseudopregnant foster
females to obtain chimeric mice.
Genotyping and southern blot analyses
Chimeras were ﬁrst genotyped using PCR assays to detect the
Tfam
þ, Tfam
loxP, Tfam
2 and cre genotypes in tail DNA, as
previously described (29). Southern blot analyses were per-
formed to assess levels of chimerism in the cerebellum of
all chimeras. Half of the cerebellum was homogenized and
total DNA was extracted. An aliquot of 3 mg DNA was
digested with BamHI, separated in 0.8% agarose, blotted
onto a nylon membrane and probed with a DNA fragment cor-
responding to the region surrounding exon 5 of the Tfam gene.
The exon 5 probe was obtained by PCR ampliﬁcation of
genomic DNA with the primer pair E5A (50-acaagcatacttca
tttacaaatccc-30) and E5B (50-gtagaaaatgttctctctcataagag-30).
The probe was labeled using the Prime-It II kit (Stratagene,
USA). Hybridized blots were analyzed with the Personal
Molecular Imager FX (BioRad, USA) and the software
Quantity One 4.6 was used to determine the proportion of
Tfam
þ and Tfam
loxP alleles. At least three independent
analyses were performed on each chimeric mouse.
Clinical scoring of symptoms and analysis
of locomotion and rearing
MILON mice reproducibly and invariably develop all ﬁve cri-
teria we used for clinical scoring of chimeras at 5 months of
age (Fig. 4A), i.e. decreased motor activity, reduced grooming,
characteristic posture with anxiety and social avoidance, and
aggressive behavior and hyperactivity in response to stress.
We developed a scoring system based on ﬁve parameters to
determine age-of-onset symptoms in cohorts of MILON
mice, control chimeras and MILON chimeras. We scored a
mouse as symptomatic when three of these ﬁve criteria were
present: (i) decreased spontaneous motor activity, (ii) unat-
tended, poorly groomed fur, (iii) kyphosis of spine, (iv) gait
disturbance with wobbly walking, (v) aggressive behavior
and/or hyperactivity in response to stress. Mice were scored
on a weekly basis from 4 months of age. We ﬁrst observed
the mouse in its normal environment (the cage). We then
repeated the observation after transferring the mouse to a
novel environment (a laboratory bench).
Immunohistochemistry and microscopy
Chimeras were subjected to transcardiac perfusion with
Ca
2þ-free Tyrode’s solution with heparin to remove blood
and thereafter ﬁxed by perfusion with a solution containing
4% paraformaldehyde and 0.4% picric acid in 0.16 M phosphate
buffer, pH 7.0. The brains were removed and post-ﬁxed over-
night in the same solution at 48C. Next, brains were equili-
brated in 10% sucrose containing 0.1% sodium azide and
stored in this solution at þ48C. Brains were frozen on CO2
ice and sectioned with a cryostat to obtain 14 mm sections.
LacZ enzyme activity was detected by incubating brain sections
with substrate at 378C overnight using a kit (Sigma). Cresyl
violet (Sigma) and FluoroJade (Chemicon) stainings (33,34)
were performed as suggested by the manufacturer. Sections
were analyzed (NIKON Eclipse E600) and images collected
using appropriate software (Spot v.4.5). Fluorescence images
corresponding to entire coronal sections of the brain were digi-
tally constructed (Photoshop to combine four smaller 5X lens
images). Bright ﬁeld images were adjusted to contain the
same background intensity and the same average signal inten-
sity per object to correct for the variation of LacZ staining.
Assessment of chimerism in neocortex and the dentate gyrus
was performed by cell counting of sections stained to detect
nuclear DNA (Hoechst 33342) and LacZ enzyme activity.
Images of double-stained sections were obtained with a decon-
volution microscope (LEICA ASMDW). Image deconvolution
was performed (Leica software) and co-localization was digi-
tally analyzed (Volocity 3D Software). Results from deconvo-
lution microscopy were conﬁrmed by confocal microscopy
(LSM 510 Meta, Zeiss, Germany) in selected cases. Assess-
ment of chimerism in neocortex was obtained by counting a
total of 99 cortical neurons of each animal at three deﬁned
locations, i.e. layer III of the retrospinal granular cortex (33
neurons), the somatosensory one-barrel ﬁeld (33 neurons) and
the piriform cortex (33 neurons). Hoescht staining was used
to identify neurons (based on location, size of the nucleus
and the presence of several nucleoli) prior to bright-ﬁeld count-
ing of the proportion of neurons expressing LacZ.
Statistical analyses
Variations in the measurements are shown as standard devi-
ation. Regression analyses were performed using appropriate
software (Excel regression tool of the Analysis Toolpack
Microsoft Ofﬁce).
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